Cerity Partners’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $897M | Buy |
747,548
+14,999
| +2% | +$15.3M | 1.08% | 15 |
|
|
2026
Q1 | $674M | Buy |
732,549
+24,369
| +3% | +$24.7M | 0.95% | 17 |
|
|
2025
Q4 | $761M | Buy |
708,180
+17,597
| +3% | +$16.8M | 1.11% | 15 |
|
|
2025
Q3 | $525M | Buy |
690,583
+83,385
| +14% | +$62.1M | 0.85% | 19 |
|
|
2025
Q2 | $472M | Buy |
607,198
+7,068
| +1% | +$5.49M | 0.84% | 19 |
|
|
2025
Q1 | $494M | Buy |
600,130
+19,315
| +3% | +$16.1M | 1% | 14 |
|
|
2024
Q4 | $453M | Buy |
580,815
+295
| +0.1% | +$244K | 0.98% | 15 |
|
|
2024
Q3 | $513M | Buy |
580,520
+50,091
| +9% | +$45M | 1.13% | 11 |
|
|
2024
Q2 | $480M | Sell |
530,429
-16,841
| -3% | -$13.5M | 1.26% | 11 |
|
|
2024
Q1 | $425M | Sell |
547,270
-35,491
| -6% | -$25.3M | 1.12% | 12 |
|
|
2023
Q4 | $156M | Buy |
582,761
+355,548
| +156% | +$208M | 0.51% | 41 |
|
|
2023
Q3 | $122M | Sell |
227,213
-32,262
| -12% | -$16.6M | 0.59% | 37 |
|
|
2023
Q2 | $122M | Buy |
259,475
+25,080
| +11% | +$10.5M | 0.47% | 44 |
|
|
2023
Q1 | $86.5M | Buy |
234,395
+10,003
| +4% | +$3.37M | 0.2% | 73 |
|
|
2022
Q4 | $83.3M | Buy |
224,392
+29,448
| +15% | +$10.4M | 0.53% | 39 |
|
|
2022
Q3 | $63M | Buy |
194,944
+3,699
| +2% | +$1.17M | 0.76% | 20 |
|
|
2022
Q2 | $62M | Buy |
191,245
+162,110
| +556% | +$48.7M | 0.69% | 25 |
|
|
2022
Q1 | $7.5M | Buy |
29,135
+6,130
| +27% | +$1.58M | 0.12% | 152 |
|
|
2021
Q4 | $5.62M | Buy |
23,005
+11,857
| +106% | +$3.01M | 0.09% | 185 |
|
|
2021
Q3 | $2.58M | Sell |
11,148
-18
| -0.2% | -$4.44K | 0.06% | 230 |
|
|
2021
Q2 | $2.56M | Sell |
11,166
-315
| -3% | -$63.3K | 0.06% | 232 |
|
|
2021
Q1 | $2.15M | Sell |
11,481
-2,050
| -15% | -$401K | 0.05% | 242 |
|
|
2020
Q4 | $2.29M | Buy |
13,531
+1,579
| +13% | +$236K | 0.07% | 192 |
|
|
2020
Q3 | $1.77M | Buy |
11,952
+3,956
| +49% | +$612K | 0.07% | 184 |
|
|
2020
Q2 | $1.31M | Buy |
7,996
+398
| +5% | +$61.1K | 0.07% | 172 |
|
|
2020
Q1 | $1.05M | Sell |
7,598
-364
| -5% | -$50K | 0.07% | 195 |
|
|
2019
Q4 | $1.05M | Sell |
7,962
-798
| -9% | -$92.5K | 0.05% | 239 |
|
|
2019
Q3 | $980K | Buy |
8,760
+4,063
| +87% | +$452K | 0.06% | 252 |
|
|
2019
Q2 | $520K | Sell |
4,697
-2,484
| -35% | -$293K | 0.03% | 309 |
|
|
2019
Q1 | $932K | Sell |
7,181
-171
| -2% | -$20.8K | 0.06% | 249 |
|
|
2018
Q4 | $851K | Buy |
7,352
+182
| +3% | +$20.3K | 0.06% | 247 |
|
|
2018
Q3 | $769K | Buy |
7,170
+549
| +8% | +$54.9K | 0.05% | 278 |
|
|
2018
Q2 | $565K | Buy |
6,621
+866
| +15% | +$71.1K | 0.04% | 311 |
|
|
2018
Q1 | $445K | Sell |
5,755
-5,543
| -49% | -$446K | 0.03% | 354 |
|
|
2017
Q4 | $954K | Buy |
11,298
+4,726
| +72% | +$402K | 0.06% | 241 |
|
|
2017
Q3 | $562K | Sell |
6,572
-6,250
| -49% | -$513K | 0.04% | 306 |
|
|
2017
Q2 | $335K | Buy |
12,822
+6,607
| +106% | +$539K | 0.03% | 279 |
|
|
2017
Q1 | $523K | Buy |
+6,215
| New | +$498K | 0.04% | 248 |
|
Other funds holding LLY
VCM
VPM
Cerity Partners's LLY Position: Q2 2026 in Review
Cerity Partners increased its Eli Lilly (LLY) stake by 2% in Q2 2026, buying an estimated $15.3M and bringing the position to 747,548 shares worth $897M. The position accounts for 1.08% of the portfolio, ranked #15.
Cerity Partners first reported a position in LLY in Q1 2017 and has held it in 38 quarters since. 4,228 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- Cerity Partners held 747,548 shares of Eli Lilly worth $897M as of Q2 2026.
- Cerity Partners bought 14,999 Eli Lilly shares in Q2 2026, an estimated $15.3M.
- Eli Lilly made up 1.08% of Cerity Partners's portfolio in Q2 2026, its #15 holding.
- Cerity Partners first reported a position in Eli Lilly in Q1 2017 and has held it in 38 quarters since.
- 4,228 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.